Phase 2 Oesophageal Cancer Trial, Recruiting NCT06687876 Sponsor: Amsterdam UMC, location VUmc Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06687876
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of cancer (adenocarcinoma) of the oesophagus (food pipe) or the area where the oesophagus meets the stomach, confirmed by a tissue test, and the cancer has not spread too far and can be removed by surgery.
  • You are planning to receive chemotherapy combined with radiotherapy before surgery (called neoadjuvant chemoradiotherapy).
  • You are 18 years of age or older.
  • You are generally well enough to carry out light daily activities — not bedridden or severely limited by your illness (confirm with trial site).
  • Your blood, kidney, and liver are working well enough, based on blood test results meeting specific levels set by the trial.
  • You are willing to have two additional camera examinations of your oesophagus (endoscopies) for research purposes.
  • You are able and willing to sign a consent form agreeing to take part voluntarily.
  • You are able to attend follow-up appointments and receive treatment at the trial centre.

Who may not be able to join:

  • You have been diagnosed with type 1 or type 2 diabetes and are currently taking medication to manage it.
  • You are currently taking metformin or any other diabetes medication for any reason.
  • You are allergic or have had a bad reaction to metformin.
  • You drink excessive amounts of alcohol.
  • You are currently taking certain medications that affect how the body processes specific drugs — including verapamil, cimetidine, dolutegravir, rifampicin, trimethoprim, vandetanib, crizotinib, olaparib, or isavuconazole (confirm with trial site if unsure about your medications).
  • You are currently taking medicines that suppress the immune system, such as steroids (corticosteroids), cyclosporine, tacrolimus, sirolimus, everolimus, or cyclophosphamide.
  • You have previously had chemotherapy, other systemic cancer treatment, or radiotherapy to the oesophagus.
  • Your kidneys are not working well enough, based on a specific blood test result.
  • You have had another type of cancer in the past 5 years, or currently have another cancer, that could affect your outlook with oesophageal cancer.
  • You have received systemic treatment for any other cancer within the last six months.
  • You have previously had a stem cell transplant or a solid organ transplant (such as a kidney or liver transplant).
  • You are pregnant, planning to become pregnant, or are currently breastfeeding.
  • You have a significant heart condition, such as a recent heart attack, unstable chest pain, heart failure, or a serious irregular heartbeat, that would make major surgery unsafe.
  • You have a serious lung condition, such as pulmonary fibrosis or active lung inflammation, that would make major surgery or radiation unsafe.
  • You have another serious medical condition that would prevent you from safely receiving the planned treatment, or you have previously had an allergic reaction to certain drugs (such as teniposide or cyclosporine) (confirm with trial site).
  • You have dementia or a condition that affects your ability to understand and agree to take part in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sarah Derks, MD PhD, Amsterdam UMC, location VUmc

Phone: +3120 44 45869

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Amsterdam UMC, location VUmc
Registry
ClinicalTrials.gov
Start date
9 March 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

activation of the tumour immune microenvironment after two week metformin treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov